Thomas Pickardt

Thomas Pickardt

Auto-generated profile, based on publicly available information

Thomas Pickardt

National Register for Congenital Heart Defects, 13353 Berlin, Germany

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ASAlejandro Sifrim
Alejandro Sifrim
MHMarc-Phillip Hitz
Marc-Phillip Hitz
AWAnna Wilsdon
Anna Wilsdon
JBJeroen Breckpot
Jeroen Breckpot
STSaeed H Al Turki
Saeed H Al Turki
MHMatthew E Hurles
Matthew E Hurles
Matthew Hurles and colleagues report exome sequencing of 1,891 individuals with syndromic or nonsyndromic congenital heart defects (CHD). They found that nonsyndromic CHD patients were enriched for protein-truncating variants in CHD-associated genes inherited from unaffected parents and identified three new syndromic CHD disorders caused by de novo mutations. Congenital heart defects (CHDs) have a neonatal incidence of 0.8–1% (refs. 1,2). Despite abundant examples of monogenic CHD in humans and mice, CHD has a low absolute sibling recurrence risk (∼2.7%)3, suggesting a considerable role for de novo mutations (DNMs) and/or incomplete penetrance4,5. De novo protein-truncating variants (PTVs) have been shown to be enriched among the 10% of 'syndromic' patients with extra-cardiac manifestations6,7. We exome sequenced 1,891 probands, including both syndromic CHD (S-CHD, n = 610) and nonsyndromic CHD (NS-CHD, n = 1,281). In S-CHD, we confirmed a significant enrichment of de novo PTVs but not inherited PTVs in known CHD-associated genes, consistent with recent findings8. Conversely, in NS-CHD we observed significant enrichment of PTVs inherited from unaffected parents in CHD-associated genes. We identified three genome-wide significant S-CHD disorders caused by DNMs in CHD4, CDK13 and PRKD1. Our study finds evidence for distinct genetic architectures underlying the low sibling recurrence risk in S-CHD and NS-CHD.

1 February 2011 in Circulation: Cardiovascular Genetics
Verified
Journal Article
Closed access
APAlex V. Postma
Alex V. Postma
KEKlaartje van Engelen
Klaartje van Engelen
JMJudith van de Meerakker
Judith van de Meerakker
TRThahira Rahman
Thahira Rahman
SPSusanne Probst
Susanne Probst
SKSabine Klaassen
Sabine Klaassen
Background—: Ebstein anomaly is a rare congenital heart malformation characterized by adherence of the septal and posterior leaflets of the tricuspid valve to the underlying myocardium. An association between Ebstein anomaly with left ventricular noncompaction (LVNC) and mutations in MYH7 encoding β-myosin heavy chain has been shown; in this report, we have screened for MYH7 mutations in a cohort of probands with Ebstein anomaly in a large population-based study. Methods and Results—: Mutational analysis in a cohort of 141 unrelated probands with Ebstein anomaly was performed by next-generation sequencing and direct DNA sequencing of MYH7 . Heterozygous mutations were identified in 8 of 141 samples (6%). Seven distinct mutations were found; 5 were novel and 2 were known to cause hypertrophic cardiomyopathy. All mutations except for 1 3-bp deletion were missense mutations; 1 was a de novo change. Mutation-positive probands and family members showed various congenital heart malformations as well as LVNC. Among 8 mutation-positive probands, 6 had LVNC, whereas among 133 mutation-negative probands, none had LVNC. The frequency of MYH7 mutations was significantly different between probands with and without LVNC accompanying Ebstein anomaly ( P <0.0001). LVNC segregated with the MYH7 mutation in the pedigrees of 3 of the probands, 1 of which also included another individual with Ebstein anomaly. Conclusions—: Ebstein anomaly is a congenital heart malformation that is associated with mutations in MYH7 . MYH7 mutations are predominantly found in Ebstein anomaly associated with LVNC and may warrant genetic testing and family evaluation in this subset of patients.

1 August 2021 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
PDF file
FSFranziska Seidel
Franziska Seidel
MHManuel Holtgrewe
Manuel Holtgrewe
NANadya Al-Wakeel-Marquard
Nadya Al-Wakeel-Marquard
BOBernd Opgen-Rhein
Bernd Opgen-Rhein
JDJosephine Dartsch
Josephine Dartsch
SKSabine Klaassen
Sabine Klaassen
Background: Myocarditis is one of the most common causes leading to heart failure in children and a possible genetic background has been postulated. We sought to characterize the clinical and genetic characteristics in patients with myocarditis ≤18 years of age to predict outcome. Methods: A cohort of 42 patients (Genetics in Pediatric Myocarditis) with biopsy-proven myocarditis underwent genetic testing with targeted panel sequencing of cardiomyopathy-associated genes. Genetics in Pediatric Myocarditis patients were divided into subgroups according to the phenotype of dilated cardiomyopathy (DCM) at presentation, resulting in 22 patients without DCM (myocarditis without phenotype of DCM) and 20 patients with DCM (myocarditis with phenotype of DCM). Results: Myocarditis with phenotype of DCM patients (median age 1.4 years) were younger than myocarditis without phenotype of DCM patients (median age 16.1 years; P <0.001) and were corresponding to heart failure–like and coronary syndrome–like phenotypes, respectively. At least one likely pathogenic/pathogenic variant was identified in 9 out of 42 patients (22%), 8 of them were heterozygous, and 7 out of 9 were in myocarditis with phenotype of DCM. Likely pathogenic/pathogenic variants were found in genes validated for primary DCM ( BAG3, DSP, LMNA, MYH7, TNNI3, TNNT2 , and TTN ). Rare variant enrichment analysis revealed significant accumulation of high-impact disease variants in myocarditis with phenotype of DCM versus healthy individuals ( P =0.0003). Event-free survival was lower ( P =0.008) in myocarditis with phenotype of DCM patients compared with myocarditis without phenotype of DCM and primary DCM. Conclusions: We report heterozygous likely pathogenic/pathogenic variants in biopsy-proven pediatric myocarditis. Myocarditis patients with DCM phenotype were characterized by early-onset heart failure, significant enrichment of likely pathogenic/pathogenic variants, and poor outcome. These phenotype-specific and age group–specific findings will be useful for personalized management of these patients. Genetic evaluation in children newly diagnosed with myocarditis and DCM phenotype is warranted.

11 July 2019 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
SSStephan Schubert
Stephan Schubert
BOBernd Opgen-Rhein
Bernd Opgen-Rhein
MBMartin Boehne
Martin Boehne
AWAnnika Weigelt
Annika Weigelt
RWRobert Wagner
Robert Wagner
TCthe MYKKE consortium
the MYKKE consortium

1 May 2017 in American Heart Journal
Verified
Journal Article
Closed access
DMDaniel R. Messroghli
Daniel R. Messroghli
TPThomas Pickardt
Thomas Pickardt
MFMarcus Fischer
Marcus Fischer
BOBernd Opgen-Rhein
Bernd Opgen-Rhein
KPKonstantin Papakostas
Konstantin Papakostas
SSStephan Schubert
Stephan Schubert

29 July 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
EAEnrique Audain
Enrique Audain
AWAnna Wilsdon
Anna Wilsdon
JBJeroen Breckpot
Jeroen Breckpot
JIJose M. G. Izarzugaza
Jose M. G. Izarzugaza
TFTomas W. Fitzgerald
Tomas W. Fitzgerald
MHMarc-Phillip Hitz
Marc-Phillip Hitz
Numerous genetic studies have established a role for rare genomic variants in Congenital Heart Disease (CHD) at the copy number variation (CNV) and de novo variant (DNV) level. To identify novel haploinsufficient CHD disease genes, we performed an integrative analysis of CNVs and DNVs identified in probands with CHD including cases with sporadic thoracic aortic aneurysm. We assembled CNV data from 7,958 cases and 14,082 controls and performed a gene-wise analysis of the burden of rare genomic deletions in cases versus controls. In addition, we performed variation rate testing for DNVs identified in 2,489 parent-offspring trios. Our analysis revealed 21 genes which were significantly affected by rare CNVs and/or DNVs in probands. Fourteen of these genes have previously been associated with CHD while the remaining genes (FEZ1, MYO16, ARID1B, NALCN, WAC, KDM5B and WHSC1) have only been associated in small cases series or show new associations with CHD. In addition, a systems level analysis revealed affected protein-protein interaction networks involved in Notch signaling pathway, heart morphogenesis, DNA repair and cilia/centrosome function. Taken together, this approach highlights the importance of re-analyzing existing datasets to strengthen disease association and identify novel disease genes and pathways.